Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
April 4, 2022 06:37 AM EDTUpdated 10:50 AM
Pharma

No­var­tis CEO Vas Narasimhan re­struc­tures the phar­ma gi­ant, cut­ting costs $1B+, oust­ing top ex­ecs and sig­nal­ing lay­offs ahead

John Carroll

Editor & Founder

No­var­tis CEO Vas Narasimhan has a plan to make the glob­al phar­ma gi­ant more prof­itable. And he’s start­ing by carv­ing out a bil­lion dol­lars-plus in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times